• Sector: Business Services
  • Location: North West
  • Website: www.fishawack.com
  • Date of investment: Mar-13
  • Exit date: Jan-17
  • GCP board members: Richard Shaw


Specialist medical communications agency providing professional services to assist large global pharmaceutical companies in educating the medical sector on pharmaceutical products that are in mid to late stage clinical trials and also supporting these products post market launch
The business was founded in 2001 by the current CEO, Oliver Dennis and CFO, Dominic Miller
The business now employs over 160 people with operations in UK, Switzerland and the US

Why we invested

Historically Fishawack had grown successfully both organically and through acquisition to become a full service medical communications agency working on global accounts for large pharmaceutical clients such as GSK, Sanofi and Novartis
The business provides a highly valued added service delivered by a professional workforce with high levels of scientific expertise
Opportunity to support the buy and build opportunity

How we are making a difference

GCP underwrote the entire transaction, providing the debt and equity on the deal
GCP funding and hands on M&A support played a key role in executing three strategic bolt-on acquisitions: Archimed, JK Associates Inc and Facilitate Limited
Following the integration of three strategic acquisitions and strong organic growth across the top 20 pharmaceutical clients, the earnings of the group more than doubled
With this increased scale an opportune time arose to realise value for Fund III whilst achieving the management objective of continuing a larger buy and build programme
GCP completed the successful sale of Fishawack Group Limited on Friday 20th January

GCP has a very strong track record of helping businesses deliver on their growth plans

Oliver Dennis Co-founder of Fishawack